Siehler S, Nunn C, Zupanc G K H, Hoyer D
Discovery Technologies, Novartis Institutes for Biomedical Research, WSJ 386/745, Novartis Pharma AG, CH 4002 Basel, Switzerland.
Auton Autacoid Pharmacol. 2005 Jan;25(1):1-16. doi: 10.1111/j.1474-8673.2004.00325.x.
1 The fish somatostatin receptor 3 (fsst3) is one of the few somatostatin (SRIF) receptors cloned from a non-mammalian species so far. Here we extended our earlier characterization of this receptor by investigating the guanine nucleotide sensitivity of agonist radioligand binding at the fsst3 receptor recombinantly expressed in CCL39 (Chinese hamster lung fibroblast) cells. Further, we measured somatostatin (SRIF) and cortistatin (CST) analogues stimulated GTPgammaS binding, inhibition of forskolin-stimulated adenylate cyclase (FSAC) and stimulation of phospholipase C (PLC) activities. The present transductional data were then compared with previous radioligand binding and/or second messenger features determined for fsst3 and/or human SRIF receptors (hsst2, hsst3 and hsst5). 2 The GTP analogue guanylylimidodiphosphate (GppNHp) inhibited binding of [125I]CGP 23996 and [125I][Tyr3octreotide by 72 and 83% suggesting preferential labelling of G-protein-coupled fsst3 receptors. By contrast, [125I]LTT-SRIF28 and [125I][Tyr10]CST14 binding was rather GppNHp insensitive (42 and 35% inhibition) suggesting labelling of both coupled and non-coupled receptor states. These results might explain the apparent higher receptor densities determined in saturation experiments with [125I]LTT-SRIF28 and [125I][Tyr10]CST14 (4470 and 4030 fmol mg(-1)) compared with [125I]CGP 23996 and [125I][Tyr3]octreotide (3420 and 1520 fmol mg(-1)). 3 SRIF14 (10 microm)-stimulated specific [35S]GTPgammaS binding by three-fold; SRIF28 and octreotide displayed full agonism, whereas most other ligands displayed 60-80% intrinsic activity compared with SRIF14. SRIF14 and SRIF28 inhibited forskolin-stimulated AC (FSAC) activity by 60%; all tested ligands except BIM 23056 inhibited FSAC with comparable high intrinsic activities. SRIF14 stimulated PLC activity five- to six-fold, as determined by measuring total [3H] IP(x) accumulation; it was rather insensitive to pertussis toxin (PTX, 100 ng ml(-1), 21% inhibition), which suggests the G(q)-family proteins couple to PLC activity. SRIF14, SRIF28 and [Tyr10]CST14 showed full agonism at PLC, whereas all other ligands behaved as partial agonists (20-70% intrinsic activity). BIM 23056, which showed weak partial or no agonism, antagonized SRIF14-induced total [3H]-IP(x) production (pK(B) = 6.83), but failed to block competitively agonist-stimulated [35S]GTPgammaS binding or agonist-induced inhibition of FSAC activity. 4 Comparison of the pharmacological profiles of fsst3 receptors established in GTPgammaS binding, FSAC inhibition and PLC stimulation resulted in low correlations (r = 0.410-0.594). Both rank orders of potency and rank orders of relative efficacy varied in the three second messenger experiments. Significant, although variable correlations were obtained comparing GTPgammaS binding and inhibition of FSAC activity with previously reported affinity profiles of [125I]LTT-SRIF28, [125I][Tyr10]CST14, [125I]CGP 23996, [125I][Tyr3]octreotide (r = 0.75-0.83; 0.68-0.89). By contrast, the PLC stimulation and radioligand-binding profiles did not correlate. 5 Comparison of the functional data (GTPgammaS binding, FSAC inhibition, PLC stimulation) of fsst3 receptors with those of human sst2, sst3, sst5 receptors expressed in CCL39 cells resulted in highest correlation with the hsst5 receptor (r = 0.94, 0.97, 0.49) > hsst2 (0.80, 0.50, n.d.) > hsst3 (0.25, 0.19, 0.17). 6 In summary, fsst3 receptors expressed in CCL39 cells are involved in signalling cascades similar to those reported for mammalian SRIF receptors, suggesting SRIF receptors to be highly conserved in evolution. Binding and functional data showed highest similarity of fsst3 receptors with the human sst5 receptor subtype. Different affinities, receptor densities and GppNHp-sensitivities determined with the four radioligands (agonists) are assumed to results from ligand-specific states of the fsst3-ligand complex. The differences in the rank orders of potency and relative efficacy in the various signalling cascades may be explained by agonist-induced receptor trafficking.
鱼类生长抑素受体3(fsst3)是目前从非哺乳动物物种中克隆出的少数生长抑素(SRIF)受体之一。在此,我们通过研究在CCL39(中国仓鼠肺成纤维细胞)细胞中重组表达的fsst3受体上激动剂放射性配体结合的鸟嘌呤核苷酸敏感性,扩展了我们对该受体的早期表征。此外,我们测量了生长抑素(SRIF)和可体松(CST)类似物刺激的GTPγS结合、对福斯可林刺激的腺苷酸环化酶(FSAC)的抑制作用以及对磷脂酶C(PLC)活性的刺激作用。然后将目前的转导数据与先前针对fsst3和/或人类SRIF受体(hsst2、hsst3和hsst5)确定的放射性配体结合和/或第二信使特征进行比较。
GTP类似物鸟苷酰亚胺二磷酸(GppNHp)抑制[125I]CGP 23996和[125I][Tyr3]奥曲肽的结合达72%和83%,表明优先标记G蛋白偶联的fsst3受体。相比之下,[125I]LTT - SRIF28和[125I][Tyr10]CST14的结合对GppNHp不敏感(抑制率为42%和35%),表明标记了偶联和非偶联的受体状态。这些结果可能解释了与[125I]CGP 23996和[125I][Tyr3]奥曲肽(3420和1520 fmol mg(-1))相比,在使用[125I]LTT - SRIF28和[125I][Tyr10]CST14进行的饱和实验中确定的明显更高的受体密度(4470和4030 fmol mg(-1))。
SRIF14(10 μM)刺激特异性[35S]GTPγS结合达三倍;SRIF28和奥曲肽表现出完全激动作用,而与SRIF14相比,大多数其他配体表现出60 - 80%的内在活性。SRIF14和SRIF28抑制福斯可林刺激的AC(FSAC)活性达60%;除BIM 23056外,所有测试配体均以相当高的内在活性抑制FSAC。通过测量总[3H] IP(x)积累确定,SRIF14刺激PLC活性五至六倍;它对百日咳毒素(PTX,100 ng ml(-1),抑制率21%)相当不敏感,这表明G(q)家族蛋白与PLC活性偶联。SRIF14、SRIF28和[Tyr10]CST14在PLC上表现出完全激动作用,而所有其他配体表现为部分激动剂(内在活性20 - 70%)。表现出弱部分激动或无激动作用的BIM 23056拮抗SRIF14诱导的总[3H]-IP(x)产生(pK(B) = 6.83),但未能竞争性阻断激动剂刺激的[35S]GTPγS结合或激动剂诱导的FSAC活性抑制。
在GTPγS结合、FSAC抑制和PLC刺激中建立的fsst3受体药理学特征比较显示相关性较低(r = 0.410 - 0.594)。在三个第二信使实验中,效价顺序和相对效力顺序均有所不同。将GTPγS结合和FSAC活性抑制与先前报道的[125I]LTT - SRIF28、[125I][Tyr10]CST14、[125I]CGP 23996、[125I][Tyr3]奥曲肽的亲和力特征进行比较,获得了显著但可变的相关性(r = 0.75 - 0.83;0.68 - 0.89)。相比之下,PLC刺激和放射性配体结合特征不相关。
将fsst3受体的功能数据(GTPγS结合、FSAC抑制、PLC刺激)与在CCL39细胞中表达的人类sst2、sst3、sst5受体的功能数据进行比较,结果与hsst5受体的相关性最高(r = 0.94、0.97、0.49)> hsst2(0.80、0.50、无数据)> hsst3(0.25、0.19、0.17)。
总之,在CCL39细胞中表达的fsst3受体参与了与哺乳动物SRIF受体报道的类似的信号级联反应,表明SRIF受体在进化中高度保守。结合和功能数据显示fsst3受体与人类sst5受体亚型的相似性最高。用四种放射性配体(激动剂)确定的不同亲和力、受体密度和GppNHp敏感性被认为是由fsst3 - 配体复合物的配体特异性状态导致的。在各种信号级联反应中效价顺序和相对效力顺序的差异可能由激动剂诱导的受体转运来解释。